GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abivax SA (STU:2X1) » Definitions » NonCurrent Deferred Liabilities

Abivax (STU:2X1) NonCurrent Deferred Liabilities : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Abivax NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Abivax's non-current deferred liabilities for the quarter that ended in Dec. 2024 was €0.00 Mil.

Abivax NonCurrent Deferred Liabilities Historical Data

The historical data trend for Abivax's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abivax NonCurrent Deferred Liabilities Chart

Abivax Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abivax Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 3.77 - -

Abivax NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Abivax's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Abivax Business Description

Industry
Traded in Other Exchanges
Address
7-11 boulevard Haussmann, Paris, FRA, 75009
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Abivax Headlines

No Headlines